Parnassia

Parnassia Therapeutics is a biotechnology company focused on the discovery and development of novel therapies for mitochondrial diseases. Founded by Deerfield Management in collaboration with Dr. Vamsi Mootha, a leading expert in mitochondrial biology from the Broad Institute and Massachusetts General Hospital, the company leverages a proprietary platform to identify genetic and metabolic interventions that can restore energy production in cells with mitochondrial dysfunction. Its research efforts target a range of rare primary mitochondrial disorders with significant unmet medical needs, such as Leigh syndrome and mitochondrial DNA depletion syndromes. Parnassia's approach involves systematic mapping of the mitochondrial proteome to uncover druggable targets. The company is currently advancing its lead small molecule programs through pre-clinical development.